US 6,982,269 B2 | ||
Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | ||
Alvin J. Glasky, Mission Viejo, Calif. (US); David B. Fick, Tustin, Calif. (US); and David Helton, Irvine, Calif. (US) | ||
Assigned to Spectrum Pharmaceuticals, Inc., Irvine, Calif. (US) | ||
Filed on Jul. 09, 2002, as Appl. No. 10/193,550. | ||
Prior Publication US 2003/0022892 A1, Jan. 30, 2003 | ||
Int. Cl. A61K 31/52 (2006.01); A61K 31/495 (2006.01); A61K 43/54 (2006.01); A61K 31/33 (2006.01) |
U.S. Cl. 514—263 | 17 Claims |
1. A method for treating cognitive/attention deficit disorders in a mammal comprising:
administering to a mammal in need thereof an effective amount of a tetrahydroindolone derivative or analogue having the schematic
structure: where:
![]() (a) A is a tetrahydroindolone moiety having the structure:
![]() where:
(i) N is bonded to L;
(ii) R5 is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,
NH2, NHQ1, NQ1Q2, OH, OQ1, or SQ1, where Q1 and Q2 are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and
can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q1 and Q2 are present together and are alkyl, they can be taken together to form a 5 or 6 member ring which may contain 1 other heteroatom
which can be N, O, or S, of which the N may be further substituted with Y2, where Y2 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl,
or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can
be N, O, or S;
(iii) R5′ is hydrogen unless R5 is alkyl, in which case R5′ is hydrogen or the same alkyl as R5;
(iv) R5 and R5′ can be taken together as a double bond to C5 and can be O, S, NQ3, or C which can be substituted with one or two groups R5, where Q3 is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl in which
the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;
(v) R6 is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, NH2, NHQ4, NQ4Q5, OH, OQ4, or SQ4, where Q4 and Q5 are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and
can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q1 and Q2 are present together and are alkyl, they can be taken together to form a 5 or 6 member ring which may contain 1 other heteroatom
which can be N, O, or S, of which the N may be further substituted with Y2, where Y2 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl,
or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can
be N, O, or S;
(vi) R6′ is hydrogen unless R6 is alkyl, in which case R6′ is hydrogen or the same alkyl as R6;
(vii) R6 and R6′ can be taken together as a double bond to C5 and can be O, S, NQ6, or C which can be substituted with one or two groups R5, and where Q6 is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and
can contain from 1 to 3 heteroatoms which can be N, O, or S;
(b) L is a hydrocarbyl moiety of 1 to 6 carbon atoms that can be cyclic, with the hydrocarbyl moiety being optionally substituted
with one or more substituents selected from the group consisting of lower alkyl, amino, hydroxy, lower alkoxy, lower alkylamino,
lower alkythio, and oxo; and
(c) B is —OZ or N(Y1)-D, where Z is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, or heteroaralkyl, D is a moiety that promotes absorption
of the derivative or analogue, and Y1 is hydrogen, alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, which, when taken with D, can form a cyclic 5- or 6-membered
saturated structure which can contain one other heteroatom which can be O, N, or S, of which N can be further substituted
with Y2, where Y2 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl,
arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl,
or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can
be N, O, or S.
wherein said cognitive/attention deficit disorder is selected from the group consisting of attention Deficit Disorder(ADD)
and Attention Deficit Hyperactivity Disorder(ADHD).
|